Formycon AG (0W4N.L)

EUR 53.2

(0.95%)

Operating Income Summary of Formycon AG

  • Formycon AG's latest annual operating income in 2023 was -369 Thousand EUR , up 97.59% from previous year.
  • Formycon AG's latest quarterly operating income in 2024 Q2 was -17.98 Million EUR , down 0.0% from previous quarter.
  • Formycon AG reported an annual operating income of -17.72 Million EUR in 2022, down -28.2% from previous year.
  • Formycon AG reported an annual operating income of -13.82 Million EUR in 2021, down -140.95% from previous year.
  • Formycon AG reported a quarterly operating income of -6.91 Million EUR for 2023 Q4, down 0.0% from previous quarter.
  • Formycon AG reported a quarterly operating income of -428 Thousand EUR for 2023 FY, up 97.59% from previous quarter.

Annual Operating Income Chart of Formycon AG (2023 - 2009)

Historical Annual Operating Income of Formycon AG (2023 - 2009)

Year Operating Income Operating Income Growth
2023 -369 Thousand EUR 97.59%
2022 -17.72 Million EUR -28.2%
2021 -13.82 Million EUR -140.95%
2020 -5.73 Million EUR -152.7%
2019 -2.27 Million EUR -131.9%
2018 7.11 Million EUR 554.03%
2017 -1.56 Million EUR 61.22%
2016 -4.04 Million EUR -708.05%
2015 665.01 Thousand EUR -23.63%
2014 870.79 Thousand EUR 111.26%
2013 -7.73 Million EUR -236.95%
2012 -2.29 Million EUR -78.54%
2011 -1.28 Million EUR -26.14%
2010 -1.01 Million EUR -433.82%
2009 -191 Thousand EUR 0.0%

Peer Operating Income Comparison of Formycon AG

Name Operating Income Operating Income Difference
Boiron SA 42.29 Million EUR 100.873%
Laboratorios Farmaceuticos Rovi, S.A. 220.25 Million EUR 100.168%
Vetoquinol SA 74.26 Million EUR 100.497%
Valneva SE -82.08 Million EUR 99.55%
AB Science S.A. -13.42 Million EUR 97.252%
Nanobiotix S.A. -26.77 Million EUR 98.622%
PHAXIAM Therapeutics S.A. -23.66 Million EUR 98.44%
Vivoryon Therapeutics N.V. -28.83 Million EUR 98.72%
BioSenic S.A. -7.04 Million EUR 94.759%
ABIVAX Société Anonyme -127.37 Million EUR 99.71%